Bionano Genomics 

0
1086
+€0.00+0% 00:00 今天

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

財報

30Jul預期
Q1 2026
下一步
-0.75
-0.7
-0.65
-0.6
預期EPS
-0.6000737
實際EPS
不適用

其他人也在關注

此清單是根據在 Stock Events 上追蹤 2Y3.MU 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Show more...
執行長
Dr. Albert A. Luderer Ph.D.
員工
98
國家
美國
ISIN
US09075F1075

上市

0 Comments

分享你的想法

FAQ

Bionano Genomics 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Muenchen 交易所,Bionano Genomics 的股票以代號 2Y3.MU 進行交易。
Bionano Genomics 下一次財報日期是什麼時候?
Bionano Genomics 將於 July 30, 2026 公布下一次財報。
Bionano Genomics 上一季度的財報如何?
2Y3.MU 上一季度的財報為每股 -0.65 EUR,預估為 -0.75 EUR,帶來 +13.64% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Bionano Genomics 有多少名員工?
截至 July 12, 2026,公司共有 98 名員工。
Bionano Genomics 位於哪個產業?
Bionano Genomics從事於Health & Wellness產業。
Bionano Genomics 何時完成拆股?
Bionano Genomics 最近沒有進行任何拆股。
Bionano Genomics 的總部在哪裡?
Bionano Genomics 的總部位於 美國 的 San Diego。